Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Buy and maintains $215 price target.
Mizuho Maintains Buy on ResMed, Maintains $215 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.